A Widely-applicable System for Structure-based Chromatographic Retention Time Prediction
Authors: G. Cimpan, E. Kolovanov, A. Vazhentsev, P. Japertas, M. McBrien
Abstract #: CR1122
A number of models have been proposed for the prediction of various types of chromatographic retention
times based on chemical structures. These models are typically limited in their applicability, either in terms
of the molecules for which accurate retention times can be performed, in terms of the type of
chromatographic method, or both. Recently, a system for structure-based prediction of retention time for
generic chromatographic methods was devised. It uses the concept of a "federation of local models" to give
accurate prediction for diverse structures, even for gradient methods. This work describes further accuracy
improvements through the incorporation of Abraham's parameter prediction. The technique involves
automated detection of when these parameters are applicable, and incorporates them accordingly. A diverse
group of structures were studied under reversed-phase and HILIC methods. The accuracy of prediction will
be compared, both with and without the use of this technology.
Applying Quality by Design Concepts to Chromatographic Method Development
Authors: G. Cimpan, T. Ponzio, T. Sinclair
Abstract #: CR1124
Quality by Design is a concept that garners much attention by the pharmaceutical industry in the quest for
greater safety and speed in bringing novel compounds to market. To be successful, Quality by Design must
be applied at every stage in the development and manufacturing process; however, one can consider
processes within drug discovery on an individual basis to apply Quality by Design principles. One such
process is the development of chromatographic methods for impurities and degradant studies. Ensuring both
robustness and optimization from an efficiency standpoint is time-consuming and difficult. Generally
method development is carried out using a trial-and-error approach, and requires a large amount of manual
data interpretation. Quality is achieved when Quality by Design is applied to the stability study process by
producing well developed, traceable, error free results, and finally into the drug product by bringing novel
products to market faster, and more cost effectively.